Clinical features of CLL patients by FcγRIIIa polymorphism type
. | FcγR V/V, n = 6 . | FcγR V/F, n = 12 . | FcγR F/F, n = 12 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 69 (54-79) | 56 (50-74) | 64 (54-79) | .14 |
| No. male (%) | 4 (66) | 7 (58) | 12 (100) | .04 |
| Median WBC count, ×109/L (range) | 59.1 (8.1-175.3) | 64.7 (2.5-152.2) | 72.6 (4.1-173.4) | .80 |
| No. stage III/IV (%) | 5 (83) | 10 (83) | 6 (50) | .32 |
| Mean prior regimens (range) | 3 (1-6) | 2 (0-6) | 2 (0-4) | .39 |
| No. prior nucleoside analog treatments (%) | 5 (83) | 5 (42) | 7 (58) | .24 |
| No. with lymphadenopathy (%) | 5 (83) | 11 (92) | 12 (100) | .39 |
| No. with infusion toxicity (%) | 3 (50) | 4 (33) | 5 (42) | .78 |
| No. partial responses | 2 | 5 | 6 | .70 |
| (95%) CI | 33 (4-78) | 42 (15-72) | 50 (21-78) | > .2 |
. | FcγR V/V, n = 6 . | FcγR V/F, n = 12 . | FcγR F/F, n = 12 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 69 (54-79) | 56 (50-74) | 64 (54-79) | .14 |
| No. male (%) | 4 (66) | 7 (58) | 12 (100) | .04 |
| Median WBC count, ×109/L (range) | 59.1 (8.1-175.3) | 64.7 (2.5-152.2) | 72.6 (4.1-173.4) | .80 |
| No. stage III/IV (%) | 5 (83) | 10 (83) | 6 (50) | .32 |
| Mean prior regimens (range) | 3 (1-6) | 2 (0-6) | 2 (0-4) | .39 |
| No. prior nucleoside analog treatments (%) | 5 (83) | 5 (42) | 7 (58) | .24 |
| No. with lymphadenopathy (%) | 5 (83) | 11 (92) | 12 (100) | .39 |
| No. with infusion toxicity (%) | 3 (50) | 4 (33) | 5 (42) | .78 |
| No. partial responses | 2 | 5 | 6 | .70 |
| (95%) CI | 33 (4-78) | 42 (15-72) | 50 (21-78) | > .2 |
WBC indicates white blood cell.